MedTrace Logo

A Study of JR-141 in Patients With Mucopolysaccharidosis Type II

NCT03128593 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2022-11-14

No results posted yet for this study

Summary

The purpose of this study in patients with mucopolysaccharidosis type II (MPS II) is below,

* to collect the safety information of JR-141
* to evaluate the plasma pharmacokinetics of JR-141
* to explore the efficacy of JR-141 on MPS II-related central nervous system symptoms and general symptoms

Conditions

  • Mucopolysaccharidosis II

Interventions

DRUG

JR-141

IV infusion (lyophilized powder), 0.01-2.0 mg/kg/week

Sponsors & Collaborators

  • JCR Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
6 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-30
Primary Completion
2017-10-04
Completion
2017-10-04

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03128593 on ClinicalTrials.gov